IGF-1 (Insulin-like Growth Factor 1) is a naturally occurring peptide hormone that plays a crucial role in growth and development, with evidence suggesting its potential in preventing severe retinopathy in premature infants and as a treatment for conditions like Rett Syndrome and growth hormone deficiency. IGF-1 LR3 is a modified analog of IGF-1, primarily explored in preclinical settings for its potential in nerve repair and muscle regeneration. Both peptides are involved in growth-related pathways, with IGF-1 having a broader range of clinical investigation in our corpus, while IGF-1 LR3 is largely studied for specific regenerative applications.
| IGF-1 | IGF-1 LR3 | |
|---|---|---|
| Drug class | growth factor | growth factor |
| Studies in corpus | 108 | 18 |
| Highest evidence tier | meta analysis | review |
| Evidence tier mix | cohort · 5 rct · 22 other · 27 case series · 1 meta analysis · 2 case report · 2 review · 12 preclinical animal · 27 in vitro · 6 | preclinical animal · 12 in vitro · 3 other · 2 review · 1 |
| Studies with explicit sample size | 10 | 1 |
| Head-to-head studies in corpus | 14 | |
Studies in our corpus that mention both IGF-1 and IGF-1 LR3 — the gold-standard direct comparison evidence.
The widespread and increasing misuse of peptides poses a significant threat to the integrity of sports and the long-term health of athletes. This comprehensive review provides crucial insights for anti-doping organizations, sports federations, and healthcar…
This research provides compelling evidence that GH and IGF-I can effectively counteract the decline in milk production during prolonged lactation, suggesting new avenues for intervention. The distinct yet complementary signaling pathways activated by each h…
This research provides compelling evidence that recombinant IGF-1 can induce targeted organ growth, rather than generalized, uncontrolled proliferation, in a developing fetus. This specificity is critical, as it suggests IGF-1 could be a safer and more effe…
This research highlights a complex interplay between IGF-1 and fetal glucose metabolism, suggesting that the in vivo effects of IGF-1 LR3 on insulin secretion are not solely due to direct actions on pancreatic beta cells. Understanding these indirect, syste…
This research highlights a highly promising therapeutic strategy for treating volumetric muscle loss, a condition with limited effective treatments. By demonstrating that localized and sustained delivery of IGF-1 via a bioactive scaffold can significantly e…
This research introduces a highly innovative, sustainable, and biologically active nerve conduit derived from a plant source, offering a compelling alternative to current nerve repair strategies. The successful integration of Alstroemeria with GelMA and con…
This research provides critical insights into the intricate mechanisms governing coordinated cardiac and vascular development, particularly during vulnerable fetal stages. Understanding how IGF-1 orchestrates this balanced growth could be pivotal for develo…
This study suggests that IGF-1 LR3 may not be an effective therapeutic strategy for reversing late-gestation intrauterine growth restriction (IUGR), even when systemic levels of IGF-1 are significantly elevated. The findings highlight the complexity of feta…
This research provides compelling evidence that sustained elevated IGF-1 during fetal development directly programs pancreatic beta-cell dysfunction, leading to reduced glucose-stimulated insulin secretion. This is a critical insight into the fetal origins …
This research highlights a critical insight into Alzheimer's disease pathology, suggesting that interventions solely focused on modifying amyloid plaques may not always translate into tangible cognitive benefits. The observed dissociation between plaque rem…
No direct head-to-head trials in our corpus. Indirect comparison only. IGF-1 has been investigated in human clinical trials, including a Phase 2 trial for Rett Syndrome and a Phase 1 trial for growth hormone deficiency where an oral SSTR5 antagonist sustained IGF-1 elevation. Meta-analyses also support its potential for preventing severe retinopathy in premature infants. Preclinical studies suggest IGF-1 can induce targeted organ growth in fetal sheep and promote muscle regeneration when delivered via bioactive scaffolds. In contrast, IGF-1 LR3 is predominantly studied in preclinical animal models, showing promise for boosting sciatic nerve repair when integrated into plant-based conduits and in exploring its effects on fetal insulin secretion. One preclinical study indicated that IGF-1 LR3 failed to boost growth in underdeveloped fetal sheep, suggesting complexities in its application for intrauterine growth restriction. The available studies do not detail specific dose-response relationships or side-effect profiles for either peptide in a comparative manner.
Looking for vendor-level purity, endotoxin, and HPLC data on IGF-1 or IGF-1 LR3? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.